Phase 3 Trial Testing Pamiparib as Maintenance Therapy for Ovarian Cancer Recruiting Patients in China

Phase 3 Trial Testing Pamiparib as Maintenance Therapy for Ovarian Cancer Recruiting Patients in China
BeiGene has started enrollment in its Phase 3 clinical trial evaluating the investigational PARP inhibitor pamiparib (BGB-290) as a maintenance therapy for ovarian cancer patients who are responding to platinum-based chemotherapy. The trial (NCT03519230) is expected to include 216 adult women with confirmed high-grade serous or endometrioid ovarian cancer, including primary peritoneal and fallopian tube cancer, across

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *